# CHANGE

**FOURTH QUARTER FISCAL 2021 EARNINGS CONFERENCE CALL** 



## Legal

#### FORWARD LOOKING STATEMENT:

This presentation contains "forward-looking statements" within the meaning of federal securities laws. Any statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements. Forward-looking statements include information concerning possible or assumed future results of operations, including, but not limited to, information and assumptions regarding fiscal year 2022, the continued length and impact of COVID-19, our pending merger with UnitedHealth Group and descriptions of our business plans and strategies. These statements often include words such as "anticipate," "expect," "suggest," "plan," "believe," "intend," "estimate," "target," "project," "should," "could," "would," "may," "will," "forecast," "outlook," "potential," "continues," "seeks," "predicts," and the negatives of these words and other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties, including, but not limited to, the the ongoing length and impact of the COVID-19 pandemic on our operations and financial results, on our customers and on national, state and local economies; new risks that may arise due to responses to the pandemic by the government, our customers and us; risks related to our pending merger with UnitedHealth Group and other factors disclosed in our Annual Report on Form 10-K for the fiscal year ended March 31, 2021 in the section entitled "Risk Factors," as such factors may be updated from time to time in our periodic filings with the SEC, and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these uncertainties, you should not place undue reliance on any forward-looking statements in this presentation. All forward-looking statements are based on information currently available to Change Healthcare and are qualified in their entirety by this cautionary statement. The statements herein speak only as of the date such statements were first made. Except to the extent required by law, Change Healthcare assumes no obligation to update any such forward-looking statements or other statements included in this presentation.

#### **NON-GAAP MEASURES DISCLOSURE:**

In the Company's earnings releases, prepared remarks, conference calls, slide presentations and webcasts, there may be use or discussion of non-GAAP financial measures. We believe such measures provide supplemental information to investors with regards to our operating performance and assist investors' ability to compare our financial results to those of other companies in the same industry. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between the comparable GAAP financial measure and each non-GAAP financial measure are included in this presentation after the consolidated financial statements. These non-GAAP financial measures are calculated and presented on the basis of methodologies other than in accordance with GAAP. These non-GAAP financial measures should be considered only as supplemental to, and not as superior to, financial measures prepared in accordance with GAAP and may be defined and calculated differently by others in the same industry.



05.27.21


## Overview and Business Update

Neil de Crescenzo President and CEO



## Change Healthcare – Fourth Quarter FY21 CEO Summary


Financial Results Q4 FY2021



Business Highlights



Accelerating Market Potential





05.27.21

## Financial Performance

Fredrik Eliasson EVP and Chief Financial Officer



### Q4 FY'21 Performance

In millions except EPS	Q4 FY'21	Q4 FY'20	% Change <sup>(2)</sup>
Consolidated Revenue \$	855	\$ 843	1.4%
Solutions Revenue	804	787	2.3%
EBITDA	198	50	292.6%
Net Income	(13)	(109)	87.9%
Diluted EPS <sup>(1)</sup>	(0.04)	(0.34)	88.0%
Adjusted EBITDA	272	264	2.9%
Adjusted Net Income	134	133	0.6%
Adjusted Diluted EPS	0.42	0.42	0.1%
Diluted Number of Shares (1)	321	320	0.5%

CH Inc

#### **Q4 FY'21 Business Highlights**

#### Solutions Revenue and Adjusted EBITDA include:

- New business wins across portfolio partially offset by COVID-19 impact
- Revenue negatively impacted by \$10 million due to lower deferred revenue as part of fair value adjustments
- Solutions revenue, net of deferred revenue impact and net of M&A activity, increased 2.2%
- Execution of synergy realization and business optimization
- Continued investment in R&D and enterprise sales

#### Adjusted Net Income of \$134 million or \$0.42 per diluted share

 Lower interest expense due to reduction in YoY average long-term debt outstanding and lower interest rates

Note 1: Prior to the McKesson exit, common units of Change Healthcare LLC are equivalent to the number of outstanding common shares of Change Healthcare Inc. and membership interests of Change Healthcare LLC held by subsidiaries of McKesson.

Note 2: Percentage change does not reflect rounding of the numbers.



## **Q4 FY'21 Segment Performance**

In millions	CH Inc.		CH Inc. CH LLC		
III IIIIIIOIIS	Q4 FY'21		Q4	FY'20	Change <sup>(2)</sup>
Segment Revenue					
S&A	\$	416	\$	419	(0.6%)
Network		198		152	30.3%
TES		227		242	(6.2%)
Postage and Elimination		23		30	(22.3%)
Purchase Accounting Adj.		(10)		-	-
Total Net Revenue		855		843	1.4%
Segment Adjusted EBITDA	- Ne	w Meth	nodo	logy <sup>(1)</sup>	
S&A	\$	144	\$	150	(4.2%)
Network		108		85	26.7%
TES		20		29	(30.7%)
Postage and Elimination		0		0	0.0%
Total Adjusted EBITDA		272		264	2.9%

#### **Q4 FY'21 Business Highlights**

#### S&A: Execution Across Segment

- Excluding the impact of divestitures, revenue grew 5.7%
- Strong overall pipeline activity
- Implementations and new wins in cloud-based El solution

#### Network: Strength in Data Solutions

- Excluding the impact of acquisitions, revenue grew 6.8%
- Double digit growth in Data Solutions and B2B Payments
- Increased volume from new solution offerings/customers
- Continued investments to expand market opportunities

#### • TES: Underlying RCM Transformation Remains Intact

- Continued positive trends in RCM win rates and deal size
- Low single digit growth in RCM excluding previously announced large contract contraction
- Executing on accelerated and expanded transformation initiatives

Note 1: CH LLC reflects incorporation of new allocation methodology as of Q1 FY2021; reconciliation is provided in the appendix. Note 2: Percentage change does not reflect rounding of the numbers.



## Q4 FY'21 Cash Generation & Liquidity

- Free Cash Flow for Q4 FY'21 of \$36 million, FY \$340 million<sup>(1)</sup>
- Adjusted Free Cash Flow for Q4 FY'21 of \$65 million, FY \$430 million<sup>(1)</sup>
- Net Debt \$4.7 billion; Leverage Ratio 5.1x<sup>(2)</sup>
- Liquidity: \$891 million
  - Cash and cash equivalents of approx. \$113 million; \$779 million undrawn secured credit facility (maturity July 2024) at quarter end
- Net Debt and Liquidity include the impact of an additional \$50 million term loan facility repayment during Q4 FY'21
- No maintenance covenants; earliest debt maturity Term Loan B March 2024

Note 1: Refer to slide 18 for details on Free Cash Flow.

Note 2: Based on Adjusted EBITDA as of March 31, 2021 in accordance with the Credit Agreement.



05.27.21

## Appendix

Q4 FY'21 Financial Statements

Q4 FY'21 and FY'20 Non-GAAP Reconciliations



Consolidated Statements of Operations (unaudited and amounts in thousands, except share and per share amounts)

	s Ended	

	2021		2020	2020			
					Change		
_	Change Healthcare Inc.				Healthcare LLC		
Revenue:						70 / 500	
Solutions revenue	\$	804,299	\$	184,161	\$	786,589	
Postage revenue	_	50,861	_	12,631	_	56,791	
Total revenue		855,160		196,792		843,380	
Operating expenses:							
Cost of operations (exclusive of depreciation and							
amortization below)		357,506		71,435		346,977	
Research and development		58,926		11,559		53,257	
Sales, marketing, general and administrative		187,606		37,389		175,725	
Customer postage		50,861		12,631		56,791	
Depreciation and amortization		154,495		30,838		89,852	
Accretion and changes in estimate with related parties,							
net		2,744		(31,349)		4,627	
Gain on sale of businesses		1,344		_		_	
Tax receivable agreement charge		_		164,633		164,633	
Goodwill impairment charge				561,164			
Total operating expenses	_	813,482		858,300	_	891,862	
Operating income (loss)		41,678		(661,508)		(48,482)	
Non-operating (income) and expense							
Interest expense, net		59,508		16,248		64,084	
Contingent consideration		_		_		(1,900)	
Loss on extinguishment of debt		1,289		_		561	
Loss from Equity Method Investment in the Joint Venture		_		276,216		_	
(Gain) loss on forward purchase contract		_		55,768		_	
Other, net		(2,253)		(169)		(3,749)	
Total non-operating (income) and expense		58,544		348,063		58,996	
Income (loss) before income tax provision (benefit)		(16,866)		(1,009,571)		(107,478)	
Income tax provision (benefit)		(3,776)		(142,690)		1,112	
Net income (loss)	\$	(13,090)	\$	(866,881)	\$	(108,590)	
Net income (loss) per common share:							
Basic and diluted	\$	(0.04)	\$	(1.64)	\$	(0.34)	
Weighted average common shares outstanding: (1)			•		•		
Basic and diluted		321,393,600		186,342,936		319,789,840	

Prior to the McKesson exit, common units of Change Healthcare LLC were equivalent to the number of outstanding common shares of Change Healthcare Inc. and membership interests of Change Healthcare LLC held by subsidiaries of McKesson.



#### Consolidated Statements of Operations (unaudited and amounts in thousands, except share and per share amounts)

		Year	Ended March	Year Ended March 31,						
		2021	2020		2020					
					Change					
	_	Change Health	icare Inc.	He	althcare LLC					
Revenue:										
Solutions revenue	\$	2,893,889 \$	184,161	\$	3,074,894					
Postage revenue	_	196,532	12,631		228,079					
Total revenue		3,090,421	196,792		3,302,973					
Operating expenses:										
Cost of operations (exclusive of depreciation and										
amortization below)		1,335,075	71,435		1,345,920					
Research and development		227,036	11,559		205,035					
Sales, marketing, general and administrative		686,645	39,893		743,311					
Customer postage		196,532	12,631		228,079					
Depreciation and amortization		591,048	30,838		315,946					
Accretion and changes in estimate with related										
parties, net		13,158	15,823		14,966					
Gain on sale of businesses		(59,143)	_		_					
Tax receivable agreement charge		_	164,633		164,633					
Goodwill impairment charge		_	561,164		_					
Total operating expenses	_	2,990,351	907,976		3,017,890					
Operating income (loss)	_	100,070	(711,184)		285,083					
Non-operating (income) and expense										
Interest expense, net		245,241	16,652		283,745					
Contingent consideration		(3,000)	_		(91					
Loss on extinguishment of debt		8,924	_		19,975					
Loss from Equity Method Investment in the Joint										
Venture		_	380,713		_					
(Gain) loss on forward purchase contract		_	(15,881)		_					
Other, net		(3,698)	(1,817)		(14,630					
Total non-operating (income) and expense	_	247,467	379,667		288,999					
Income (loss) before income tax provision (benefit)		(147,397)	(1,090,851)		(3,916					
Income tax provision (benefit)		(35,187)	(143,254)		1,701					
Net income (loss)	\$	(112,210) \$	(947,597)	\$	(5,617					
	_									
Net income (loss) per common share:										
Basic and diluted	\$	(0.35) \$	(6.92)	\$	(0.02					
Weighted average common shares outstanding: (1)				-	-					
		320,771,789	136,996,624							

Prior to the McKesson exit, common units of Change Healthcare LLC were equivalent to the number of outstanding common shares of Change Healthcare Inc. and membership interests of Change Healthcare LLC held by subsidiaries of McKesson.



#### **Consolidated Balance Sheets**

(unaudited and amounts in thousands, except share and per share amounts)

	м	arch 31, 2021	March 31, 2020		
Assets					
Current assets:					
Cash and cash equivalents	\$	113,101	\$	410,405	
Accounts receivable, net		732,614		740,105	
Contract assets, net		132,856		132,704	
Prepaid expenses and other current assets		140,258		117,967	
Total current assets		1,118,829	_	1,401,181	
Property and equipment, net		174,370		206,196	
Operating lease right-of-use assets, net		93,412		_	
Goodwill		4,108,792		3,795,325	
Intangible assets, net		4,187,072		4,365,806	
Investment in business purchase option		_		146,500	
Other noncurrent assets, net		430,141		192,372	
Total assets	\$	10,112,616	\$	10,107,380	
Liabilities			_		
Current liabilities:					
Accounts payable	\$	57,449	\$	68,169	
Accrued expenses	•	484,293	•	390,294	
Deferred revenue		436,666		302,313	
Due to related parties, net		10,766		20,234	
Current portion of long-term debt		27,339		278,779	
Current portion of operating lease liabilities		30,608		_	
Total current liabilities		1,047,121	_	1,059,789	
Long-term debt, excluding current portion		4,734,775		4,710,294	
Long-term operating lease liabilities		75,396		_	
Deferred income tax liabilities		605,291		615.904	
Tax receivable agreement obligations to related parties		103,151		177,826	
Tax receivable agreement obligations		229,082		164,633	
Other long-term liabilities		65,572		93,487	
Total liabilities		6,860,388	_	6,821,933	
Commitments and contingencies					
Stockholders' Equity					
Common Stock (par value, \$.001), 9,000,000,000 and 9,000,000,000					
shares authorized and 306,796,076 and 303,428,142 shares issued and					
outstanding at March 31, 2021 and 2020, respectively		307		303	
Preferred stock (par value, \$.001), 900,000,000 shares authorized and					
no shares issued and outstanding at both March 31, 2021 and 2020		_		_	
Additional paid-in capital		4,283,391		4,222,580	
Accumulated other comprehensive income (loss)		11,221		(7,372)	
Accumulated deficit		(1,042,691)	_	(930,064)	
Total stockholders' equity		3,252,228	_	3,285,447	
Total liabilities and stockholders' equity	\$	10,112,616	\$	10,107,380	



#### Consolidated Statements of Cash Flows (unaudited and amounts in thousands)

Contained by Table (1987)         Table (1987) <th< th=""><th>(Unavairea ana amounts</th><th>ini</th><th></th><th>Ended March 2</th><th>,</th></th<>	(Unavairea ana amounts	ini		Ended March 2	,
Costs flows from operating activities         Change leathboate with electhoare (loss)         (112.210)         (947.597)         (\$   55.617)           Adjustments to reconcile net income (loss) to net cash provided by (used in) potending activities:         \$   112.210)         (947.597)         \$   55.617)           Depreciation and mortization on Ammorization of caphilazized software developed for sale Ammorization of caphilazized software developed for sale and property of the potential of the potentia					
Note Income (pics)   \$   (112.210)   \$   (947.597)   \$   (5.617)		_		2020	
Net income (loss)   (112.20)   (147.597)   (5.617)		_	Change Healt	hcare Inc.	Healthcare LLC
Adjustments to reconcile net income [loss] to net cash provided by Jused in Josephia packfilles:  Depreciation and mortization provided by Jused in Josephia 30,538 315,946  Amortization of capitalized software developed for sale 13,226 — 14,415  Accretion and changes in estimate, net 11,644 15,823 14,965  Equity compensation 59,016 1,701 31,808  Deferred income fox expense (benefit) (50,114) (143,822) [2,413)  Amortization of debt discount and issuance costs 32,532 2,235 18,807  Contingent consideration (3,000) — (97)  Gain on sole of businesses (59,143) — (15,881)				10.17.5071	
by   used in  operating activities:   Depreciation and amortization   S91,048   30,538   315,946   Amortization of capitalized software developed for sole   1,326   — 14,415   Accretion and changes in estimate, net   11,144   1,523   14,946   Equity compensation   S90,164   1,701   31,803   2,243   1,946   Equity compensation   S90,164   1,701   31,803   2,243   2,235   18,807   Confingent consideration   G10,001   G10,0		\$	(112,210) \$	(947,597)	\$ [5,017]
Depreciation and moritation					
Accrefion and changes in estimate, net   11,644   15,823   14,966   Early compensation   59016   1,701   31,802   12,613   10,000   10,0			591,048	30,838	315,946
Equity compensation   59,016   1,701   31,808			1,326	_	
Deferred income tax expense (benefit)   (50,114)   (143,822)   (2,613)   Amortization of debt discount and issuance costs   (3,000)					
Amortization of debt discount and issuance costs  Conflingent consideration  Golin on sole of businesses  Lots on extinguishment of debt  (Solin) loss on other investments  Non-cosh lease expense  Goodwill imporiment charge  Loss from Equity Method Investment in the Joint Venture  Loss from Equity Method Investment in Method Investment in Method Equity Securities of the Joint Venture  Loss from Equity Method Investment in Met					
Contingent consideration   (3,000)   — (91)					
Canin or sole of businesses   (59.143)				2,235	
Loss on extinguishment of debt				_	(91)
Colin   loss on other investments				_	10 075
Non-cosh lease expense   29,114			0,724	(15.881)	17,773
Loss from Equity Method Investment in the Joint Venture			29,114	(,,	_
Case	Goodwill impairment charge		_	561,164	_
Chier, net			_	380,713	_
Changes in operating assets and liabilities:			_		
Contract assets, net			11,257	(1,110)	6,896
Contract assets, net Prepaid expenses and other assets Accounts payable Deferred revenue 164,477 11,304 32,648 32,648 32,648 32,648 32,648 33,309 33,097 33,309  Cash flows from investing activities Capitalized expenditures Capitalized expenditures Capitalized expenditures  Capitalized expenditures (244,381) 113,002 (258,576) Acquisitions, net of cash acquired Acquisitions in the Joint Venture Investment in Revolving Facility Accounts account of the Joint Venture Investment in Revolving Facility Accounts account of the Joint Venture Investment in Account of the Joint Venture Investment in Account of the Joint Venture Investment in Revolving Facility Accounts account of the Joint Venture Investment in Account Office of The Joint Venture Inves					
Prepolic expenses and other assets				(21,211)	
Accounts payable Accrued expenses and other liabilities Acrued expenses and other liabilities Deferred revenue 164,477 11,304 Due to the Joint Venture, net Due to related party, net Due to related to the Joint Venture Cash flows from side of businesses Troceeds from sale of businesses Deferred to relate the Joint Venture Investment in debt and equity securities of the Joint Venture Deferred to relate the Joint Venture Due to the Joint Venture Due to relate the Joint Venture Due to				/4 0101	
Accrued expenses and other liabilities					
Deferred revenue					
Due to the Joint Venture, net   C					
Net cash provided by (used in) operating activities   586,196   153,928   593,309			_		_
Cash flows from investing activities:   Capitalized expenditures   (244,381)   (13,002)   (258,576)     Acquisitions, net of cash acquired   (439,483)   (330,667   (18,994)     Proceeds from sale of businesses   (115,733   —   —   29,837     Investment from sale of real estate   —   (610,784)   —     Investment in the Joint Venture   —   (610,784)   —     Investment in debt and equity securifies of the Joint Venture   —   (278,875)   —     Chier, net   —   (278,875)   —     Net cash provided by (used in) investing activities   (568,032)   (564,662)   (247,735)     Net cash provided by (used in) investing activities   (568,032)   (564,662)   (247,735)     Net cash provided by (used in) investing activities   (568,032)   (564,662)   (247,735)     Net cash provided by (used in) investing activities   (20,000)   —   —   —   —   —   —   —   —   —	Due to related party, net		_	_	(3,532)
Capitalized expenditures			586,196	(153,928)	593,309
Acquisitions, net of cash acquired   439,483   330,667   [18,994]     Proceeds from sale of businesses   115,733					
Proceeds from sale of real estate					
Proceeds from sole of real estate				330,667	[18,994]
Investment in the Joint Ventrue   Capta   Ca			115,/33	_	20.927
Case			_	(610.784)	27,007
Net cash provided by (used in) investing activities			_		_
Cosh lows from financing activities:         250,000			2,099		(2)
Payments on Revolving Facility	Net cash provided by (used in) investing activities		(568,032)	(564,662)	(247,735)
Proceeds from Revolving Facility         250,000         250,000           Payments on Term Loan Facility         (315,000)         — (1,087,750)           Proments in Suance of Senior Notes         325,000         —           Payments under tax receivable agreements         (20,641)         —         (27,227)           Receipts (payments) on derivative instruments         (29,538)         (890)         935           Employee tax withholding on vesting of equity compensation awards         (4,108)         —         —           Payment of senior amortizing notes         (19,519)         —         (6,593)           Payment of behis issued to Change Healthcare Inc.         —         —         (7,332)           Payment of debt issued to Change Healthcare Inc.         —         —         (7,332)           Proceeds from exercise of equity words         —         —         —         (7,332)           Capital contribution from Members from exercise of equity         —         —         608,679         —           Proceeds from initial public offering, net of issuance costs         —         —         608,679         —           Proceeds from Change Healthcare Inc. initial public offering sunnece of equity component of tangible equity units, net of issuance costs         —         47,367         —           Proceeds from					
Payments on Term Loan Facility   315,000			(250,000)	_	_
Proceeds from issuance of Senior Notes   235,000				250,000	
Payments under tax receivable agreements				_	(1,087,750)
Receipts (payments) on derivative instruments   (29,538)   (890)   935					(27.227)
Employee tax withholding on vesting of equity compensation owards				(890)	
Description			(21,000)	(0.0)	,
Payment of senior amortizing notes   (15,636)   (11,094)   (17,322)			(4,108)	_	_
Payment of debt issued to Change Healthcare Inc.   -   -   -				_	(6,593)
Proceeds from exercise of equity owards			(15,636)	(11,094)	_
Capital contribution from Members from exercise of equity compensation awards			-	_	(7,332)
Compensation awards			17,514	_	_
Proceeds from initial public offering, net of issuance costs			_	_	6.256
Proceeds from Change Healthcare Inc. Initial public offering			_	608,679	_
units         —         47,367         —           Proceeds from debt issued to Change Healthcare Inc.         —         —         47,367           Proceeds from issuance of equity component of tanglible equity units, net of issuance costs         —         232,929         —           Proceeds from forward purchase contract with Change         —         —         232,929           Healthcare Inc.         —         —         —         232,929           Net cash provided by (used in) financing activities         (318,778)         1,125,570         14,240           Effect of exchange rate changes on cash and cash equivalents         3,310         16         1,10,211           Net increase (decrease) in cash and cash equivalents         (297,304)         40,696         358,793           Cash and cash equivalents at beginning of period         410,405         3,409         4,884			_		608,679
Proceeds from debt issued to Change Healthcare Inc.   47.867	Proceeds from issuance of debt component of tangible equity				
Proceeds from issuance of equity component of tangible equity units, net of issuance costs   232,929			_	47,367	
units, net of issuance costs         —         232,929         —           Proceeds from forward purchase contract with Change         —         232,929           Chier, net         (6,800)         (1,421)         (3,024)           Net cash provided by (used in) financing activities         (318,778)         1,125,570         14,240           Effect of exchange rate changes on cash and cosh equivalents         3,310         16         (1,021)           Net increase (decrease) in cosh and cosh equivalents         (297,304)         406,996         385,793           Cash and cosh equivalents to beginning of period         410,405         3,409         4,894			_	_	47,367
Proceeds from forward purchase contract with Change         4         232,929           Healthcare inc.         (5,800)         (1,421)         (3,024)           Net cash provided by (used in) financing activities         (318,778)         1,125,570         14,240           Effect of exchange rate changes on cash and cash equivalents         3,310         16         (1,021)           Net increase (decrease) in cash and cash equivalents         (297,304)         405,976         358,793           Cash and cash equivalents to beginning of period         410,405         3,407         48,894			_	232 929	_
Other, net         (6,800)         (1,421)         (3,024)           Net cash provided by (used in) financing activities         (318,778)         1,125,570         14,240           Effect of exchange rate changes on cash and cash equivalents         3,310         16         (1,021)           Net increase (decrease) in cash and cash equivalents         (297,304)         405,976         358,778           Cash and cash equivalents to beginning of period         410,405         3,407         48,894				202,727	
Net cash provided by (used in) financing activities         (318,778)         1,125,570         14,240           Effect of exchange rate changes on cash and cash equivalents         3,310         16         (1,021)           Net increase (decrease) in cash and cash equivalents         (297,304)         406,979         358,793           Cash and cash equivalents at beginning of period         410,405         3,409         4,884			_	_	232,929
Effect of exchange rate changes on cash and cosh equivalents         3.310         1.6         [1,021]           Net increase (decreacy in cosh and cosh equivalents         (297.304)         406.996         358,739           Cash and cash equivalents to beginning of period         107.405         3.409         48,894		_			
Net increase (decrease) in cash and cash equivalents         (297,304)         406,996         358,793           Cash and cash equivalents at beginning of period         410,405         3,409         48,894		_			
Cash and cash equivalents at beginning of period 410,405 3,409 48,894		_			
		_			
<u>φ 110,101 φ 410,403 φ 407,007</u>		4			
	Sam and dan equivalents at end of period	φ	0,101	, 410,400	+ 407,007

#### Reconciliation of Net Income (Loss) to Adjusted EBITDA (unaudited and amounts in thousands)

Three Months Ended March 31,

			•		<u></u>	
	_	2021		2020		2020
					(	Change
		Change Healt	hca	re Inc. (1)	Hea	lthcare LLC
Net income (loss)	\$	(13,090)	\$	(866,881)	\$	(108,590)
Income tax provision (benefit)		(3,776)		(142,690)		1,112
Income (loss) before income tax provision (benefit)		(16,866)		(1,009,571)		(107,478)
Amortization of capitalized software developed for sale		776				3,959
Depreciation and amortization		154,495				89,852
Interest expense, net		59,508				64,084
Equity compensation		24,158				6,893
Acquisition accounting adjustments		5,917				522
Acquisition and divestiture-related costs		9,590				1,664
Integration and related costs		13,094				15,131
Strategic initiatives, duplicative and transition costs		8,671				8,991
Severance costs		2,717				7,824
Accretion and changes in estimate, net		3,215				4,627
Management fees and related costs		_				2,647
Impairment of long-lived assets and other		3,772				1,347
Tax receivable agreement charge		_				164,633
Gain on sale of business		1,344				_
Contingent consideration		_				(1,900)
Loss on extinguishment of debt		1,289				560
Other non-routine, net		365				1,002
Adjusted EBITDA	\$	272,045			\$	264,358

Prior to the McKesson exit, Change Healthcare Inc. did not utilize adjusted EBITDA as a key performance metric, therefore we have not presented a reconciliation to adjusted EBITDA for the three months ended March 31, 2020.



#### Reconciliation of Net Income (Loss) to Adjusted EBITDA (unaudited and amounts in thousands)

Year Ended March 31,

2021	2020	2020
		Change
Change Healt	hcare Inc.(1)	Healthcare LLC
\$ (112,210) \$	(947,597)	\$ (5,617)
(35,187)	(143,254)	1,701
(147,397)	(1,090,851)	(3,916)
1,326		14,415
591,048		315,946
245,241		283,745
59,016		31,808
109,743		1,889
19,709		4,217
40,675		82,108
21,841		23,325
13,184		22,113
11,644		14,966
_		10,355
18,190		72
_		164,633
(59,143)		_
(3,000)		(91)
8,924		19,975
3,164		10,173
\$ 934,165		\$ 995,733
\$ -	Change Healt \$ (112,210) \$ (35,187) (147,397) 1,326 591,048 245,241 59,016 109,743 19,709 40,675 21,841 13,184 11,644 — 18,190 — (59,143) (3,000) 8,924 3,164	Change Healthcare Inc. (1) \$ (112,210) \$ (947,597)

Prior to the McKesson exit, Change Healthcare Inc. did not utilize adjusted EBITDA as a key performance metric, therefore we have not presented a reconciliation to adjusted EBITDA for the year ended March 31, 2020.



Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss) (unaudited and amounts in thousands, except share and per share amounts)

		Three Mor	March 31,			
	2021 2020			2020		
					Change	
Net income (loss)	Change Healthcare Inc. (1)				lthcare LLC	
	\$	(13,090) \$	(866,881)	\$	(108,590)	
Amortization expense resulting from acquisition method						
adjustments		117,362			35,251	
EBITDA adjustments		74,132			213,942	
Tax effect of EBITDA adjustments and amortization						
expense		(44,413)			(7,417)	
Adjusted net income (loss)	\$	133,991		\$	133,186	
Adjusted net income (loss) per diluted share (2)	\$	0.42		\$	0.42	

	Year Ended March 31,					
	2021		2020		2020	
				С	hange	
	Cl	nange Healthc	are Inc. (1)	Healt	hcare LLC	
Net income (loss)	\$	(112,210) \$	(947,597)	\$	(5,617)	
Amortization expense resulting from acquisition method						
adjustments		463,334			139,875	
EBITDA adjustments		243,947			385,542	
Tax effect of EBITDA adjustments and amortization						
expense		(166,324)			(52,168)	
Adjusted net income (loss)	\$	428,747		\$	467,632	
Adjusted net income (loss) per diluted share (2)	\$	1.34		\$	1.55	

Prior to the McKesson exit, Change Healthcare Inc. did not utilize adjusted net income (loss) as a key performance metric, therefore we have not presented a reconciliation to adjusted net income (loss) for the three months and year ended March 31, 2020.



Prior to the McKesson exit, Common units of Change Healthcare LLC were equivalent to the number of outstanding common shares of Change Healthcare Inc. and membership interests of Change Healthcare LLC held by subsidiaries of McKesson.

#### Segment Results (unaudited and amounts in thousands)

	2021		2020	2020		
					Change	
		Change Healtho	Healthcare LLC (2)			
Segment revenue						
Software and Analytics	\$	416,265	N/A	\$	418,658	
Network Solutions		198,334	N/A		152,163	
Technology-Enabled Services		227,311	N/A		242,444	
Postage and Eliminations (3)		23,391	N/A		30,115	
Purchase Accounting Adjustment (4)		(10,141)	N/A		_	
Net revenue	\$	855,160	N/A	\$	843,380	
Segment adjusted EBITDA						
Software and Analytics	\$	144,025	N/A	\$	150,341	
Network Solutions		108,147	N/A		85,340	
Technology-Enabled Services		19,873	N/A		28,677	
Postage and Eliminations		_	N/A		_	
Total adjusted EBITDA	\$	272,045	N/A	\$	264,358	

#### Year Ended March 31,

		2021	2020	2020		
		Change Healthcare Inc. (1)		Change Healthcare LLC (2)		
Segment revenue						
Software and Analytics	\$	1,534,926	N/A	\$	1,612,800	
Network Solutions		717,843	N/A		588,748	
Technology-Enabled Services		869,349	N/A		978,684	
Postage and Eliminations (3)		96,533	N/A		122,741	
Purchase Accounting Adjustment (4)		(128,230)	N/A		_	
Net revenue	\$	3,090,421	N/A	\$	3,302,973	
Segment adjusted EBITDA						
Software and Analytics	\$	526,129	N/A	\$	565,628	
Network Solutions		377,005	N/A		331,659	
Technology-Enabled Services		31,031	N/A		98,446	
Postage and Eliminations		_	N/A		_	
Total adjusted EBITDA	\$	934,165	N/A	\$	995,733	

Prior to the McKesson exit, Change Healthcare Inc. did not have revenues from customers and did not utilize adjusted EBITDA as a key performance metric.



The prior year results of Change Healthcare LLC have been retrospectively adjusted to be consistent with the Company's current segment structure and cost allocation methodology.

Revenue for Postage and Eliminations includes postage revenue of \$50.9 million for Change Healthcare Inc. for the three months ended March 31, 2021 and \$56.8 million for Change Healthcare LLC for the three months ended March 31, 2020. Revenue for Postage and Eliminations includes postage revenue of \$196.5 million for Change Healthcare Inc. for the year ended March 31, 2021 and \$228.1 million for Change Healthcare LLC for the year ended March 31, 2020.

Amount reflects the impact to deferred revenue resulting from the McKesson exit which reduced revenue recognized during the three months and year ended March 31, 2021.

## Reconciliation of Cash Provided by (Used in) Operating Activities to Free Cash Flow and Adjusted Free Cash Flow

(unaudited and amounts in thousands)

		Year Ended March 31,					
	2021		2020	2020			
						Change	
		Change Healthcare Inc. (1)		Healthcare LLC			
Cash provided by (used in) operating activities (2)	\$	586,196	\$	(153,928)	\$	593,309	
Capital expenditures		(246,381)		(13,002)		(258,576)	
Free cash flow		339,815		(166,930)		334,733	
Adjustments to free cash flow (3):							
Integration and related costs		40,675				82,108	
Strategic initiatives, duplicative and transition costs		21,841				23,325	
Severance costs		13,184				22,113	
Integration and strategic capital expenditures		14,379				19,254	
Adjusted free cash flow	\$	429,894			\$	481,533	

Prior to the McKesson exit, Change Healthcare Inc. did not utilize adjusted free cash flow as a key performance metric, therefore we have not presented a reconciliation to adjusted free cash flow for the year ended March 31, 2020.



Includes cash used by pass-thru funds of \$12.8 million for Change Healthcare Inc. for the year ended March 31, 2021 and cash provided by pass-thru funds of \$21.7 million for Change Healthcare LLC for the year ended March 31, 2020.

All operating costs and integration and strategic capital expenditures are presented on an as-incurred basis.

## Change Healthcare LLC

### SEGMENT ADJUSTED EBITDA (unaudited, amounts in thousands)

	Software and Analytics		Network Solutions	_	Technology- Enabled Services	Postage and Eliminations		Total
Fiscal Year 2020:								
First Quarter	\$ 176,50	\$	79,222	\$	25,333	\$ _	\$	281,056
Second Quarter	110,990	}	79,526		27,174	_		217,693
Third Quarter	127,793	}	87,571		17,262	_		232,626
Fourth Quarter	150,34		85,340		28,677	_		264,358
Total	\$ 565,629	\$	331,659	\$	98,445	\$ _	\$	995,733
Fiscal Year 2019:								
First Quarter	\$ 121,098	\$	76,852	\$	29,798	\$ _	\$	227,749
Second Quarter	117,13	2	78,775		20,045	_		215,952
Third Quarter	126,410	,	83,367		24,294	_		234,077
Fourth Quarter	154,434	1	78,191		24,556	_		257,180
Total	\$ 519,08	\$	317,185	\$	98,693	\$ _	Ş	934,958

Note: During the first quarter of fiscal year 2021, the Company decided to allocate all administrative and certain other corporate expenses to the respective reportable segments. This allocation methodology differs from the methodology utilized by the Joint Venture in prior fiscal years. Therefore, the Adjusted EBITDA of the Joint Venture's reportable segments has been retrospectively adjusted for those periods to be consistent with the Company's current allocation methodology.



## CHANGE HEALTHCARE

Insight. Innovation. Transformation.